论文部分内容阅读
目的:对瑞舒伐他汀对于老年冠心病伴高胆固醇血症患者的疗效及其安全性的讨论及分析。方法:对某医院2011年1月1日至2014年12月31日所接收的80例患有老年冠心病伴高胆固醇血症的患者的临床资料进行随机分组,主要将患者分为试验组和实验对照组,并进行分析。对于试验组患者,医护人员将采取辛伐他汀进行治疗,而医护人员将对实验对照组进行瑞舒伐他汀进行治疗。结果:患者在通过不同的方法进行治疗后,其LDL-C及TC的水平值均出现下降现象,并具有明显差异性。而试验对照组通过辛伐他汀治疗后,LDL-C、TC值均比试验组低。而试验对照组患者在接受治疗后出现不良反应的概率也比试验组低8.7%。经分析,上述两组数据均具有统计学意义,可以使用。结论:瑞舒伐他汀对于老年冠心病伴高胆固醇血症患者来说,不仅可以有效降低患者的各项指标,并且,较传统方法来说,造成的不良反应后果较低,是一种疗效好,不良反应低的好方法,在临床应用上具有深远意义,并值得推广。
Objective: To discuss and analyze the efficacy and safety of rosuvastatin in elderly patients with coronary heart disease and hypercholesterolemia. Methods: The clinical data of 80 patients with senile coronary heart disease with hypercholesterolemia received from a hospital from January 1, 2011 to December 31, 2014 were randomly divided into two groups: the experimental group and the control group Experimental control group, and analysis. For the test group of patients, medical staff will take simvastatin for treatment, and medical staff will be on the experimental control group rosuvastatin for treatment. Results: After treatment by different methods, the levels of LDL-C and TC in patients decreased, with significant differences. The experimental control group after simvastatin treatment, LDL-C, TC values were lower than the experimental group. The trial control group of patients receiving the treatment of adverse reactions after the probability of 8.7% lower than the experimental group. After analysis, the above two groups of data are statistically significant, can be used. Conclusion: Rosuvastatin not only can effectively reduce the patient’s indicators of elderly patients with coronary heart disease and hypercholesterolemia, and, compared with the traditional method, the adverse consequences caused by lower, is a good effect , A good method of low adverse reactions, has far-reaching clinical significance, and is worth promoting.